Cargando…
Management of VEGFR-Targeted TKI for Thyroid Cancer
SIMPLE SUMMARY: Anti-VEGFR therapy has become a mainstay of treatment for thyroid cancer across histological subtypes. However, the inhibition of this pathway is associated with particular adverse effects, some of which are life-threatening and may lead to the withdrawal of definitive treatment. To...
Autores principales: | Enokida, Tomohiro, Tahara, Makoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583039/ https://www.ncbi.nlm.nih.gov/pubmed/34771698 http://dx.doi.org/10.3390/cancers13215536 |
Ejemplares similares
-
Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions
por: Enokida, Tomohiro, et al.
Publicado: (2021) -
Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer
por: Kang, Soyoung, et al.
Publicado: (2023) -
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018) -
Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
por: Matsuyama, Chihiro, et al.
Publicado: (2023) -
Management of recurrent or metastatic thyroid cancer
por: Tahara, Makoto
Publicado: (2018)